These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14709149)

  • 1. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals.
    Giltay EJ; Toorians AW; Sarabdjitsingh AR; de Vries NA; Gooren LJ
    J Endocrinol; 2004 Jan; 180(1):107-12. PubMed ID: 14709149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Male-pattern baldness and incident coronary heart disease and risk factors in the Heinz Nixdorf Recall Study.
    Pechlivanis S; Heilmann-Heimbach S; Erbel R; Mahabadi AA; Hochfeld LM; Jöckel KH; Nöthen MM; Moebus S
    PLoS One; 2019; 14(11):e0225521. PubMed ID: 31743359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness.
    Bang HJ; Yang YJ; Lho DS; Lee WY; Sim WY; Chung BC
    J Dermatol Sci; 2004 Feb; 34(1):11-6. PubMed ID: 14757277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
    Ryu HK; Kim KM; Yoo EA; Sim WY; Chung BC
    Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females.
    Gooren LJG; Giltay EJ
    J Sex Med; 2008 Apr; 5(4):765-776. PubMed ID: 17971101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals.
    Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R
    J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
    Mueller A; Kiesewetter F; Binder H; Beckmann MW; Dittrich R
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3470-5. PubMed ID: 17579193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals.
    Caanen MR; Schouten NE; Kuijper EAM; van Rijswijk J; van den Berg MH; van Dulmen-den Broeder E; Overbeek A; van Leeuwen FE; van Trotsenburg M; Lambalk CB
    Hum Reprod; 2017 Jul; 32(7):1457-1464. PubMed ID: 28505246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
    van Kesteren PJ; Asscheman H; Megens JA; Gooren LJ
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):337-42. PubMed ID: 9373456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease.
    Ades PA; Savage PD; Toth MJ; Schneider DJ; Audelin MC; Bunn JY; Ludlow M
    Int J Obes (Lond); 2008 Jun; 32(6):967-74. PubMed ID: 18268512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obstructive sleep apnea, low transferrin saturation levels, and male-pattern baldness.
    Baik I; Lee S; Thomas RJ; Shin C
    Int J Dermatol; 2019 Jan; 58(1):67-74. PubMed ID: 30144036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of androgen treatment on bone metabolism in female-to-male transsexuals.
    Lips P; van Kesteren PJ; Asscheman H; Gooren LJ
    J Bone Miner Res; 1996 Nov; 11(11):1769-73. PubMed ID: 8915785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baldness and coronary heart disease risk factors.
    Trevisan M; Farinaro E; Krogh V; Jossa F; Giumetti D; Fusco G; Panico S; Mellone C; Frascatore S; Scottoni A
    J Clin Epidemiol; 1993 Oct; 46(10):1213-8. PubMed ID: 8410106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia.
    Quirós C; Patrascioiu I; Mora M; Aranda GB; Hanzu FA; Gómez-Gil E; Godás T; Halperin I
    Endocrinol Nutr; 2015 May; 62(5):210-6. PubMed ID: 25790747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimüllerian hormone levels decrease in female-to-male transsexuals using testosterone as cross-sex therapy.
    Caanen MR; Soleman RS; Kuijper EA; Kreukels BP; De Roo C; Tilleman K; De Sutter P; van Trotsenburg MA; Broekmans FJ; Lambalk CB
    Fertil Steril; 2015 May; 103(5):1340-5. PubMed ID: 25772768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.
    Ruetsche AG; Kneubuehl R; Birkhaeuser MH; Lippuner K
    Osteoporos Int; 2005 Jul; 16(7):791-8. PubMed ID: 15502960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Male pattern baldness is not associated with established cardiovascular risk factors in the general population.
    Ellis JA; Stebbing M; Harrap SB
    Clin Sci (Lond); 2001 Apr; 100(4):401-4. PubMed ID: 11256978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs take part in pathophysiology and pathogenesis of Male Pattern Baldness.
    Goodarzi HR; Abbasi A; Saffari M; Tabei MB; Noori Daloii MR
    Mol Biol Rep; 2010 Jul; 37(6):2959-65. PubMed ID: 19821055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of three different testosterone formulations in female-to-male transsexual persons.
    Pelusi C; Costantino A; Martelli V; Lambertini M; Bazzocchi A; Ponti F; Battista G; Venturoli S; Meriggiola MC
    J Sex Med; 2014 Dec; 11(12):3002-11. PubMed ID: 25250780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp.
    Hibberts NA; Howell AE; Randall VA
    J Endocrinol; 1998 Jan; 156(1):59-65. PubMed ID: 9496234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.